Novavax (NVAX) Stock Price Drops 5% as BofA Starts at Underperform, Sees 40% Downside Risk
Tweet Send to a Friend
Bank of America analyst Alec Stranahan initiated research coverage on Novavax (NASDAQ: NVAX) with an Underperform rating and a $35.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
